According to a market report by Lucintel, the future of the global generic injectable market looks promising with opportunities in the oncology, anesthesia, anti-infective, parenteral nutrition, and cardiovascular disease markets. The global generic injectable market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the increasing demand for cost-effective treatment options, the rising prevalence of chronic health conditions, and the growing approvals of generic injectable drugs.
A more
than 150-page report to understand trends, opportunity and forecast in global generic
injectable market to 2031 by type (small molecule and large molecule),
application (oncology, anesthesia, anti-infectives, parenteral nutrition, cardiovascular
diseases, and others), and region (North America, Europe, Asia Pacific, and the
Rest of the World).
Lucintel
forecasts that, within the type category, small molecule is expected to witness
higher growth over the forecast period.
Within the
application category, parenteral nutrition is expected to witness the highest
growth.
Download
sample by clicking on generic
injectable market.
In terms
of region, APAC is expected to witness the highest growth over the forecast
period.
Hospira,
Fresenius Kabi, Sandoz, Hikma Pharmaceuticals, Dr. Reddy’s Laboratories,
Grifols, Nichi-Iko Group, Teva Pharmaceutical, Auromedics, Sanofi are the major
suppliers in the generic
injectable market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com to get
access of more than 1000 reports at fraction of cost visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Major Histocompatibility Complex (MHC) Tetramer Sales Market
300mm Wafer Clean Machine Market
Absorbable Perirectal Spacer Market
No comments:
Post a Comment